Research graph
References from Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy. Local targets link to admitted publications; unresolved targets remain external evidence.
Pancreatic Cancer: Advances and Challenges
10.1016/j.cell.2023.02.014 · 2023 · External reference
Pancreatic Cancer: A Review
10.1001/jama.2021.13027 · 2021 · External reference
The Actual 5‐Year Survivors of Pancreatic Ductal Adenocarcinoma Based on Real‐World Data
10.1038/s41598-020-73525-y · 2020 · External reference
Update on the Management of Pancreatic Cancer: Surgery Is Not Enough
10.3748/wjg.v21.i11.3157 · 2015 · External reference
Neoadjuvant Treatment of Pancreatic Ductal Adenocarcinoma: Whom, When and How
10.4240/wjgs.v16.i5.1223 · 2024 · External reference
Advances in Neoadjuvant Therapy for Pancreatic Cancer: Current Trends and Future Directions
2025 · External reference
Modification of the 8th AJCC Staging System of Pancreatic Ductal Adenocarcinoma
10.21037/hbsn.2019.08.01 · 2020 · External reference
Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy
10.1097/pas.0000000000000887 · 2017 · External reference
A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA‐Score
10.1097/sla.0000000000004143 · 2022 · External reference
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX
10.1097/sla.0000000000006650 · 2025 · External reference
Pancreatic Body and Tail Adenocarcinoma: Upfront Resection Versus Neoadjuvant Therapy, A Contemporary Analysis
10.1097/mpa.0000000000002372 · 2024 · External reference
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2023.0034 · 2023 · External reference
Reconsidering the Absence of Extrapancreatic Extension in T Staging for Pancreatic Adenocarcinoma in the AJCC (8th ed) Staging Manual Using the National Cancer Database
10.1007/s11605-023-05850-2 · 2023 · External reference
A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach
10.1097/pas.0000000000001601 · 2021 · External reference
Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0
10.1148/radiol.2016142043 · 2016 · External reference
Prognostic Models to Predict Survival in Patients With Pancreatic Cancer: A Systematic Review
10.1016/j.hpb.2022.01.011 · 2022 · External reference
The Role of Neoadjuvant Therapy in Pancreatic Cancer: A Review
10.2217/fon.15.335 · 2016 · External reference
Pathology After Neoadjuvant Treatment—How to Assess Residual Disease
10.1016/j.breast.2021.11.009 · 2022 · External reference
Carbohydrate Antigen 19‐9—Tumor Marker: Past, Present, and Future
10.4240/wjgs.v12.i12.468 · 2020 · External reference
Influence of Lewis α1‐3/4‐l‐Fucosyltransferase (FUT3) Gene Mutations on Enzyme Activity, Erythrocyte Phenotyping, and Circulating Tumor Marker Sialyl‐Lewis a Levels
10.1074/jbc.271.50.32260 · 1996 · External reference
Tumors of the Pancreatic Body and Tail
2010 · External reference
Metabolic Activity by FDG‐PET/CT After Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer and Association With Survival
10.1093/bjs/znab229 · 2021 · External reference
FDG‐PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
10.6004/jnccn.2022.7041 · 2022 · External reference
The Role of FDG PET/CT or PET/MRI in Assessing Response to Neoadjuvant Therapy for Patients With Borderline or Resectable Pancreatic Cancer: A Systematic Literature Review
10.1007/s12149-021-01629-0 · 2021 · External reference
Pancreatic Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow‐Up
10.1016/j.annonc.2023.08.009 · 2023 · External reference
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2021.0017 · 2021 · External reference
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
10.1200/jco.19.02274 · 2020 · External reference
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial
10.1001/jamaoncol.2022.2319 · 2022 · External reference
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial
10.1001/jama.2016.4324 · 2016 · External reference
Circulating Tumor Cells as Predictive and Prognostic Biomarkers in Solid Tumors
10.3390/cells12222590 · 2023 · External reference
Monitoring of Circulating Tumour DNA in Advanced Pancreatic Ductal Adenocarcinoma Predicts Clinical Outcome and Reveals Disease Progression Earlier Than Radiological Imaging
10.1002/1878-0261.13472 · 2023 · External reference
